TDI-11861

TDI-11861 is an orally active soluble sAC inhibitor optimized and designed based on TDI-10229 (HY-132298), with an IC50 of 3.3 nM and a KD of 1.4 nM. TDI-11861 has advantages such as high affinity, slow dissociation, and good pharmacokinetics. TDI-11861 can be used for research on male contraception and related sAC pharmacology[1][2].

Product Specifications

CAS Number

[2857049-72-8]

UNSPSC

12352005

Target

Adenylate Cyclase

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/tdi-11861.html

Concentration

10mM

Purity

99.35

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

NC1=NC(C2=NN(C=C2CC3=C(C=CC=C3)OCCN4CCOC[C@H]4CO)C(F)F)=CC(Cl)=N1

Molecular Formula

C22H25ClF2N6O3

Molecular Weight

494.92

References & Citations

[1]Miller M, et al. Design, Synthesis, and Pharmacological Evaluation of Second-Generation Soluble Adenylyl Cyclase (sAC, ADCY10) Inhibitors with Slow Dissociation Rates. J Med Chem. 2022 Nov 8. |[2]Kim J, et al. Advances in Male Contraception: When Will the Novel Male Contraception be Available? World J Mens Health. 2024 Jul;42 (3) :487-501.